Nai Kong V Cheung

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. pmc KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma
    Jeffrey M Venstrom
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 15:7330-4. 2009
  2. doi request reprint Neuroblastoma: developmental biology, cancer genomics and immunotherapy
    Nai Kong V Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Nat Rev Cancer 13:397-411. 2013
  3. pmc Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission
    Nai Kong V Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Clin Oncol 30:3264-70. 2012
  4. pmc Expression of the neuron-specific protein CHD5 is an independent marker of outcome in neuroblastoma
    Idoia Garcia
    Developmental Tumor Biology Laboratory, Hospital Sant Joan de Deu, Fundación Sant Joan de Déu, Barcelona, Spain
    Mol Cancer 9:277. 2010
  5. pmc Specific gene expression profiles and chromosomal abnormalities are associated with infant disseminated neuroblastoma
    Cinzia Lavarino
    Developmental tumour biology laboratory, Hospital Sant Joan de Deu, Fundació Sant Joan de Déu, Barcelona, Spain
    BMC Cancer 9:44. 2009
  6. ncbi request reprint Detection of metastatic neuroblastoma in bone marrow: when is routine marrow histology insensitive?
    N K Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 15:2807-17. 1997
  7. ncbi request reprint Anti-idiotypic antibody facilitates scFv chimeric immune receptor gene transduction and clonal expansion of human lymphocytes for tumor therapy
    Nai Kong V Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Hybrid Hybridomics 22:209-18. 2003
  8. ncbi request reprint Orally administered beta-glucans enhance anti-tumor effects of monoclonal antibodies
    Nai Kong V Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Cancer Immunol Immunother 51:557-64. 2002
  9. ncbi request reprint Anti-idiotypic antibody as the surrogate antigen for cloning scFv and its fusion proteins
    Nai Kong V Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Hybrid Hybridomics 21:433-43. 2002
  10. ncbi request reprint FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor
    Nai Kong V Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 24:2885-90. 2006

Research Grants

Detail Information

Publications104 found, 100 shown here

  1. pmc KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma
    Jeffrey M Venstrom
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 15:7330-4. 2009
    ..We hypothesized that patients with a "missing ligand" KIR-HLA compound genotype may uniquely benefit from autologous hematopoietic stem cell transplantation (HSCT)...
  2. doi request reprint Neuroblastoma: developmental biology, cancer genomics and immunotherapy
    Nai Kong V Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Nat Rev Cancer 13:397-411. 2013
    ..In this Review we discuss the key discoveries in the developmental biology, molecular genetics and immunology of neuroblastoma, as well as new translational tools for bringing these promising scientific advances into the clinic...
  3. pmc Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission
    Nai Kong V Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Clin Oncol 30:3264-70. 2012
    ..Anti-GD2 monoclonal antibody (MoAb) combined with granulocyte-macrophage colony-stimulating factor (GM-CSF) has shown efficacy against neuroblastoma (NB). Prognostic variables that could influence clinical outcome were explored...
  4. pmc Expression of the neuron-specific protein CHD5 is an independent marker of outcome in neuroblastoma
    Idoia Garcia
    Developmental Tumor Biology Laboratory, Hospital Sant Joan de Deu, Fundación Sant Joan de Déu, Barcelona, Spain
    Mol Cancer 9:277. 2010
    ..CHD5 gene and protein expression was reexamined after induction chemotherapy in a subset of high risk tumors to identify potential changes reflecting tumor response...
  5. pmc Specific gene expression profiles and chromosomal abnormalities are associated with infant disseminated neuroblastoma
    Cinzia Lavarino
    Developmental tumour biology laboratory, Hospital Sant Joan de Deu, Fundació Sant Joan de Déu, Barcelona, Spain
    BMC Cancer 9:44. 2009
    ..The aim of this study was to investigate chromosomal alterations and differential gene expression amongst infant disseminated NB subgroups...
  6. ncbi request reprint Detection of metastatic neuroblastoma in bone marrow: when is routine marrow histology insensitive?
    N K Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 15:2807-17. 1997
    ..To measure the sensitivity of histologic examination in detecting metastatic solid tumor in bone marrow...
  7. ncbi request reprint Anti-idiotypic antibody facilitates scFv chimeric immune receptor gene transduction and clonal expansion of human lymphocytes for tumor therapy
    Nai Kong V Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Hybrid Hybridomics 22:209-18. 2003
    ..Anti-idiotypic antibody may provide a useful tool for optimizing gene transduction of CIR fusion constructs into primary human lymphocytes and their continual expansion in vitro...
  8. ncbi request reprint Orally administered beta-glucans enhance anti-tumor effects of monoclonal antibodies
    Nai Kong V Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Cancer Immunol Immunother 51:557-64. 2002
    ..Given the favorable efficacy and toxicity profile of oral beta- D-glucan treatment, the role of natural products that contain beta-glucan in cancer treatment as an enhancer of the effect of mAb therapy deserves further study...
  9. ncbi request reprint Anti-idiotypic antibody as the surrogate antigen for cloning scFv and its fusion proteins
    Nai Kong V Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Hybrid Hybridomics 21:433-43. 2002
    ..The reduced size resulted in a shorter half-life in vivo, while achieving comparable tumor to nontumor ratio as the native antibody 8H9. However, its in vitro activity in antibody-dependent cell-mediated cytotoxicity was modest...
  10. ncbi request reprint FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor
    Nai Kong V Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 24:2885-90. 2006
    ..Granulocyte macrophage colony-stimulating factor (GM-CSF) enhances phagocyte-mediated ADCC. The differential affinity of the human FCGR polymorphic alleles for 3F8 may influence the effectiveness of antibody immunotherapy...
  11. ncbi request reprint Single-chain Fv-streptavidin substantially improved therapeutic index in multistep targeting directed at disialoganglioside GD2
    Nai Kong V Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 45:867-77. 2004
    ..Neuroblastoma is uniquely suited for such investigations because of its abundance of surface ganglioside GD2...
  12. ncbi request reprint Oral (1-->3),(1-->4)-beta-D-glucan synergizes with antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma
    Nai Kong V Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 8:1217-23. 2002
    ..We tested if (1-->3),(1-->4)-beta-D-glucan (beta-glucan) can synergize with anti-GD2 monoclonal antibody (MoAb) 3F8 (mouse IgG3) in therapy of human neuroblastoma xenografts...
  13. ncbi request reprint Induction of Ab3 and Ab3' antibody was associated with long-term survival after anti-G(D2) antibody therapy of stage 4 neuroblastoma
    N K Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 6:2653-60. 2000
    ..Ab3 and Ab3' antibody response correlated with prolonged PFS and survival. We postulate that successful induction of an idiotype network in patients may be responsible for long-term tumor control...
  14. ncbi request reprint Detection of neuroblastoma in bone marrow by immunocytology: is a single marrow aspirate adequate?
    N K Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Med Pediatr Oncol 32:84-7. 1999
    ..We examined whether the chance of a positive IC from a single marrow site was comparable to an IC of pooled marrow from multiple sites...
  15. ncbi request reprint Monoclonal antibody-based therapy for neuroblastoma
    N K Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Curr Oncol Rep 2:547-53. 2000
    ..Experience with metastatic neuroblastoma has provided proof of this principle. It is likely that other tumors will fall...
  16. ncbi request reprint Correlation of anti-idiotype network with survival following anti-G(D2) monoclonal antibody 3F8 therapy of stage 4 neuroblastoma
    N K Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Med Pediatr Oncol 35:635-7. 2000
    ..1998): J Clin Oncol 16:3053] following antibody 3F8 (Ab1) treatment. We postulate that the induction of an idiotype network which included anti-anti-idiotypic (Ab3) and anti-G(D2) (Ab3') responses is associated with tumor control...
  17. ncbi request reprint Detection of microscopic disease: comparing histology, immunocytology, and RT-PCR of tyrosine hydroxylase, GAGE, and MAGE
    I Y Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Med Pediatr Oncol 36:210-2. 2001
    ....
  18. ncbi request reprint N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age
    N K Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Med Pediatr Oncol 36:227-30. 2001
    ....
  19. ncbi request reprint Monoclonal antibody-based therapy of neuroblastoma
    N K Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Hematol Oncol Clin North Am 15:853-66. 2001
    ..Ongoing strategies to modify or reconstruct mAbs, to engage them with cytokines, or to unite them with T cells open new avenues for harnessing the unique forces of the immune system against some of the most deadly pediatric cancers...
  20. ncbi request reprint Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age
    N K Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 16:3053-60. 1998
    ..To eradicate minimal residual disease with anti-G(D2) monoclonal antibody 3F8 in stage 4 neuroblastoma (NB) diagnosed at more than 1 year of age...
  21. ncbi request reprint Quantitation of GD2 synthase mRNA by real-time reverse transcriptase polymerase chain reaction: clinical utility in evaluating adjuvant therapy in neuroblastoma
    Irene Y Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 21:1087-93. 2003
    ..Because therapy (myeloablation, immunotherapy, or differentiation) for MRD is applied at the time of clinical remission, objective surrogate markers are needed to gauge treatment efficacy...
  22. doi request reprint A focal lesion in the falx cerebri: Harbinger of classic stage 4 neuroblastoma in an infant cured despite residual disease after minimal therapy
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Pediatr Blood Cancer 53:1340-2. 2009
    ..The falx cerebri probably does not represent an atypical site for stage 4S NB, but stage 4 NB with favorable biology is sometimes curable with minimal therapy...
  23. pmc Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma
    Kim Kramer
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 429, New York, NY 10065, USA
    J Neurooncol 97:409-18. 2010
    ..The cRIT-salvage regimen for CNS metastases was well tolerated by young patients, despite their prior history of intensive cytotoxic therapies. It has the potential to increase survival with better than expected quality of life...
  24. ncbi request reprint High-dose cyclophosphamide inhibition of humoral immune response to murine monoclonal antibody 3F8 in neuroblastoma patients: broad implications for immunotherapy
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
    Pediatr Blood Cancer 48:430-4. 2007
    ..We assessed the impact on rapid HAMA formation of prior chemotherapy in NB patients...
  25. ncbi request reprint Radioimmunotargeting of human rhabdomyosarcoma using monoclonal antibody 8H9
    Shakeel Modak
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Cancer Biother Radiopharm 20:534-46. 2005
    ..5 MBq (131)I-8H9 were significantly suppressed compared to controls. Radiolabeled 8H9 effectively targeted RMS xenografts and may have a potential clinical role in radioimmunotherapy...
  26. ncbi request reprint Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Clin Oncol 22:4888-92. 2004
    ..We now describe similar results with changes that reduce toxicity (fewer cycles, less vincristine, use of granulocyte colony-stimulating factor)...
  27. doi request reprint Hypothyroidism after 131I-monoclonal antibody treatment of neuroblastoma
    Sonal Bhandari
    Department of Pediatrics, New York Presbyterian Weill Cornell Medical College, New York, New York, USA
    Pediatr Blood Cancer 55:76-80. 2010
    ..To determine the prevalence of and risk factors for primary hypothyroidism following treatment with a radiolabeled monoclonal antibody ((131)I-3F8) in children with neuroblastoma...
  28. ncbi request reprint Quantitation of GD2 synthase mRNA by real-time reverse transcription-polymerase chain reaction: utility in bone marrow purging of neuroblastoma by anti-GD2 antibody 3F8
    Irene Y Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 94:3042-8. 2002
    ..Its utility in bone marrow (BM) purging is evaluated by a real-time reverse transcription-polymerase chain reaction (RT-PCR) assay to quantify the mRNA of GD2 synthase, the key enzyme in GD2 synthesis...
  29. pmc Solitary relapse of desmoplastic small round cell tumor detected by positron emission tomography/computed tomography
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 26:4995-6. 2008
  30. ncbi request reprint Prognostic value of MYCN and ID2 overexpression in neuroblastoma
    Miguel Alaminos
    Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
    Pediatr Blood Cancer 45:909-15. 2005
    ..The molecular mechanisms driven by overexpression of the MYCN gene in neuroblastoma are not well known. Whether MYCN overexpression in the absence of genomic amplification, or ID2 overexpression has prognostic value remains controversial...
  31. ncbi request reprint Impact of metaiodobenzylguanidine scintigraphy on assessing response of high-risk neuroblastoma to dose-intensive induction chemotherapy
    Brian H Kushner
    Departments of Medical Imaging and Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 21:1082-6. 2003
    ..We present the first report on the effect of MIBG scans on the classification of response to dose-intensive induction therapy...
  32. ncbi request reprint Camptothecin analogs (irinotecan or topotecan) plus high-dose cyclophosphamide as preparative regimens for antibody-based immunotherapy in resistant neuroblastoma
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Clin Cancer Res 10:84-7. 2004
    ..067 mg/kg was injected on day 1. With C/I, irinotecan, 50 mg/m(2) was infused i.v. (1 h) on days 1-5 (total, 250 mg/m(2)). Mesna and granulocyte colony-stimulating factor were used...
  33. doi request reprint High-dose carboplatin-irinotecan-temozolomide: treatment option for neuroblastoma resistant to topotecan
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Pediatr Blood Cancer 56:403-8. 2011
    ..We report a retrospective study of a novel regimen for neuroblastoma (NB) resistant to standard induction or salvage chemotherapy which now routinely includes topotecan...
  34. pmc Cyclin D1, a novel molecular marker of minimal residual disease, in metastatic neuroblastoma
    Irene Y Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Mol Diagn 9:237-41. 2007
    ..We conclude that CCND1 has potential clinical utility as a novel molecular marker of MRD in the bone marrow of patients with metastatic NB...
  35. pmc Management and outcome of stage 3 neuroblastoma
    Shakeel Modak
    Department of Paediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Eur J Cancer 45:90-8. 2009
    ..We describe a single centre approach at Memorial Sloan-Kettering Cancer Centre (MSKCC) from 1991 to 2007 that minimises therapy except for those patients with MYCN-amplified NB...
  36. doi request reprint Reduced risk of secondary leukemia with fewer cycles of dose-intensive induction chemotherapy in patients with neuroblastoma
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Pediatr Blood Cancer 53:17-22. 2009
    ..We report a prospective study of secondary leukemia (SL)/myelodysplastic syndrome (MDS) in neuroblastoma (NB) patients treated with > or =5 cycles of dose-intensive chemotherapy...
  37. doi request reprint Differential impact of high-dose cyclophosphamide, topotecan, and vincristine in clinical subsets of patients with chemoresistant neuroblastoma
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer 116:3054-60. 2010
    ....
  38. pmc Two-compartment model of radioimmunotherapy delivered through cerebrospinal fluid
    Ping He
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065 USA corrected
    Eur J Nucl Med Mol Imaging 38:334-42. 2011
    ..We now describe a two-compartment model to account for the ventricular reservoir of (131)I-3F8 and to identify limiting factors that may impact therapeutic ratio...
  39. ncbi request reprint Long-term complications in survivors of advanced stage neuroblastoma
    Caroline Laverdiere
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Pediatr Blood Cancer 45:324-32. 2005
    ..Few studies have assessed late effects in neuroblastoma (NB) survivors, particularly those with advanced stage disease...
  40. ncbi request reprint Early molecular response of marrow disease to biologic therapy is highly prognostic in neuroblastoma
    Irene Y Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 21:3853-8. 2003
    ..To use early marrow response as a prognostic marker is particularly relevant for patients not likely to benefit from this therapy...
  41. ncbi request reprint Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of alpha-emitting atomic nanogenerators targeting disialo-ganglioside GD2
    Matthias Miederer
    Departments of Molecular Pharmacology and Chemistry, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 10:6985-92. 2004
    ..The (225)Ac-3F8 treatment improved survival 2-fold from 16 to 34 days (P = 0.01). In conclusion, in vivo alpha generators targeted by 3F8 warrant additional study as a possible new approach to the treatment of carcinomatous meningitis...
  42. pmc Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment
    Nidale Tarek
    Department of Pediatrics, Sloan Kettering Institute, New York, NY 10065, USA
    J Clin Invest 122:3260-70. 2012
    ..These results indicate that unlicensed NK cells play a key antitumor role in patients undergoing mAb therapy via antibody-dependent cell-mediated cytotoxicity, thus explaining the potent "missing KIR ligand" benefit in patients with NB...
  43. doi request reprint Whole neuraxis irradiation to address central nervous system relapse in high-risk neuroblastoma
    Victoria J Croog
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Radiat Oncol Biol Phys 78:849-54. 2010
    ..This study describes the use of craniospinal irradiation (CSI) for CNS relapse and compares outcomes to patients who received focal radiotherapy (RT)...
  44. ncbi request reprint Treatment of spinal involvement in neuroblastoma patients
    David I Sandberg
    Department of Surgery, Division of Neurosurgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, N Y 10021, USA
    Pediatr Neurosurg 39:291-8. 2003
    ..Considerable controversy exists regarding the appropriate management of spinal involvement in neuroblastoma (NB) patients. We review a large group of such patients and offer treatment recommendations...
  45. ncbi request reprint Rituximab therapy of lymphoma is enhanced by orally administered (1-->3),(1-->4)-D-beta-glucan
    Shakeel Modak
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, USA
    Leuk Res 29:679-83. 2005
    ..No clinical toxicity was observed. The therapeutic efficacy and lack of toxicity of this combination supports further investigation into its clinical utility...
  46. doi request reprint Hyperfractionated low-dose (21 Gy) radiotherapy for cranial skeletal metastases in patients with high-risk neuroblastoma
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Int J Radiat Oncol Biol Phys 75:1181-6. 2009
    ..To present a large experience (73 patients) using a standard radiotherapy (RT) protocol to prevent relapse in cranial sites where measurable metastatic neuroblastoma (NB), an adverse prognostic marker, is common...
  47. ncbi request reprint Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates
    Matthias Miederer
    Department of Molecular Pharmacology and Chemistry, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 45:129-37. 2004
    ..However, the 3 alpha-emitting daughter elements generated have the potential for significant toxicity as these nuclides are no longer bound to the carrier IgG...
  48. ncbi request reprint Neuroblastoma in adolescents and adults: the Memorial Sloan-Kettering experience
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Med Pediatr Oncol 41:508-15. 2003
    ..We reviewed the utility of different treatment modalities in a large series of adolescents/adults with neuroblastoma (NB)...
  49. ncbi request reprint Liver involvement in neuroblastoma: the Memorial Sloan-Kettering Experience supports treatment reduction in young patients
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
    Pediatr Blood Cancer 46:278-84. 2006
    ..We reviewed clinical and biologic findings in a series of infants with neuroblastoma (NB) in liver. The aim was to gain insights into improving therapy...
  50. ncbi request reprint Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8
    Kim Kramer
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:5465-70. 2007
    ..We tested the toxicity, pharmacokinetics, and dosimetry of intraventricular iodine-131-labeled monoclonal antibody 3F8 (131I-3F8) targeting GD2-positive CNS/LM disease in a phase I clinical trial...
  51. doi request reprint Ifosfamide, carboplatin, and etoposide for neuroblastoma: a high-dose salvage regimen and review of the literature
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer 119:665-71. 2013
    ..A major reason for using this regimen was the long time since patients received previous treatment with a platinum compound. The authors also summarized the published experience on ICE in patients with NB...
  52. ncbi request reprint Irinotecan plus temozolomide for relapsed or refractory neuroblastoma
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 24:5271-6. 2006
    ..To report on an irinotecan and temozolomide regimen for neuroblastoma (NB). Quality of life and minimizing toxicity were major considerations...
  53. ncbi request reprint Oral topotecan for refractory and relapsed neuroblastoma: a retrospective analysis
    Kim Kramer
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Pediatr Hematol Oncol 25:601-5. 2003
    ..Although toxicity was generally thought to be mild, the efficacy of such an approach remains unproven...
  54. ncbi request reprint Sialyltransferase STX (ST8SiaII): a novel molecular marker of metastatic neuroblastoma
    Irene Y Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Cancer 119:152-6. 2006
    ..Similarly, the STX transcript level of posttreatment marrows was also highly prognostic of outcome (PFS, p = 0.001; OS, p < 0.0005). We conclude that STX mRNA has potential clinical utility as a molecular marker of metastatic NB...
  55. pmc Successful multifold dose escalation of anti-GD2 monoclonal antibody 3F8 in patients with neuroblastoma: a phase I study
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Clin Oncol 29:1168-74. 2011
    ..We hypothesized that 3F8 dose escalation is possible without increased analgesic requirements in patients pretreated with HM3F8...
  56. doi request reprint High-dose cyclophosphamide-irinotecan-vincristine for primary refractory neuroblastoma
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Eur J Cancer 47:84-9. 2011
    ..We used a novel regimen for neuroblastoma (NB) that had responded inadequately to standard chemotherapy which now includes topotecan in induction or second-line therapy...
  57. pmc Sensitivity of surveillance studies for detecting asymptomatic and unsuspected relapse of high-risk neuroblastoma
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    J Clin Oncol 27:1041-6. 2009
    ..Relapse-free survival (RFS) is a powerful measure of treatment efficacy. We describe the sensitivity of standard surveillance studies for detecting relapse of neuroblastoma (NB)...
  58. ncbi request reprint Curability of recurrent disseminated disease after surgery alone for local-regional neuroblastoma using intensive chemotherapy and anti-G(D2) immunotherapy
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Pediatr Hematol Oncol 25:515-9. 2003
    ..The authors report on a series of patients who had distant recurrences after surgery alone for local-regional neuroblastoma...
  59. doi request reprint Posterior reversible encephalopathy syndrome in neuroblastoma patients receiving anti-GD2 3F8 monoclonal antibody
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Cancer 119:2789-95. 2013
    ..In this report, the authors describe PRES associated with antidisialoganglioside (anti-GD2 ) monoclonal antibody (MoAb) immunotherapy, which is now standard for high-risk neuroblastoma but has not previously been implicated in PRES...
  60. ncbi request reprint Genome-wide analysis of gene expression associated with MYCN in human neuroblastoma
    Miguel Alaminos
    Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Cancer Res 63:4538-46. 2003
    ....
  61. doi request reprint Early negative minimal residual disease in bone marrow after immunotherapy is less predictive of late or non-marrow relapse among patients with high-risk stage 4 neuroblastoma
    Irene Y Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Pediatr Blood Cancer 60:E32-4. 2013
    ..We conclude that negative MRD in the post-cycle two BM was rarely associated with BM relapse, but it did not exclude recurrences at other sites...
  62. doi request reprint Recurrent metastatic neuroblastoma followed by myelodysplastic syndrome: possible leukemogenic role of temozolomide
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Pediatr Blood Cancer 51:552-4. 2008
    ..Salvage therapy featured 11 cycles of temozolomide. She developed myelodysplastic syndrome with 45,XX,der(7)t(7;21) (p15;q11),-21 at age 24 and refused treatment; 19 months later she was transfusion-dependent but her NB remained in CR...
  63. ncbi request reprint Novel markers of subclinical disease for Ewing family tumors from gene expression profiling
    Irene Y Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 13:6978-83. 2007
    ..Genome-wide expression arrays can uncover novel genes differentially expressed in tumors over normal marrow/blood, which may have potentials as markers of subclinical disease...
  64. ncbi request reprint Tumor lysis syndrome, neuroblastoma, and correlation between serum lactate dehydrogenase levels and MYCN-amplification
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
    Med Pediatr Oncol 41:80-2. 2003
  65. ncbi request reprint The impact of gross total resection on local control and survival in high-risk neuroblastoma
    Michael P La Quaglia
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Pediatr Surg 39:412-7; discussion 412-7. 2004
    ..The authors reviewed their institutional experience to assess the effect of primary tumor resection on local control and overall survival...
  66. ncbi request reprint Favorable-biology neuroblastoma presenting with leptomeningeal metastases?: a case presentation
    Kim Kramer
    Department of Pediatrics, Sloan Kettering Cancer Center, New York, New York, USA
    J Pediatr Hematol Oncol 26:703-5. 2004
    ..This case illustrates that some infants with favorable-biology neuroblastoma may be observed without treatment despite the advanced INSS stage...
  67. pmc MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomas
    Ruimin Huang
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    FASEB J 25:4138-49. 2011
    ....
  68. ncbi request reprint Brain-sparing radiotherapy for neuroblastoma skull metastases
    Suzanne L Wolden
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Pediatr Blood Cancer 50:1163-8. 2008
    ..The purpose of this study was to describe the technique, outcome and toxicities in patients with high risk NB metastatic to the skull treated with brain-sparing skull radiotherapy (BSRT)...
  69. ncbi request reprint Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 107:417-22. 2006
    ....
  70. ncbi request reprint Chronic neuroblastoma
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 95:1366-75. 2002
    ..An indolent course is associated with neuroblastoma (NB) in adolescents and adults. In the current study, the authors analyzed this phenomenon in a large series of children with metastatic NB...
  71. ncbi request reprint Disialoganglioside directed immunotherapy of neuroblastoma
    Shakeel Modak
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer Invest 25:67-77. 2007
    ..We review the current status of anti-GD2 clinical trials for neuroblastoma and novel preclinical GD2-targeted strategies for this rare but often lethal childhood cancer...
  72. ncbi request reprint Transient sialoadenitis: a complication of 131I-metaiodobenzylguanidine therapy
    Shakeel Modak
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Pediatr Blood Cancer 50:1271-3. 2008
    ..5] days. Serum lipase remained normal. Patients did not develop subsequent dry mouth or dysphagia...
  73. ncbi request reprint Five-day courses of irinotecan as palliative therapy for patients with neuroblastoma
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 103:858-62. 2005
    ..Quality of life was a major issue in choosing this regimen for patients whose disease was resistant to standard anti-NB therapies...
  74. ncbi request reprint Antibody-based targeted radiation to pediatric tumors
    Shakeel Modak
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Nucl Med 46:157S-63S. 2005
    ..Without substantial policy changes in drug development for orphan indications, however, these agents are not likely to be widely available in the near future...
  75. ncbi request reprint Evolving significance of prognostic markers associated with treatment improvement in patients with stage 4 neuroblastoma
    Jaume Mora
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 94:2756-65. 2002
    ....
  76. doi request reprint Neuroblastoma: Therapeutic strategies for a clinical enigma
    Shakeel Modak
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, United States
    Cancer Treat Rev 36:307-17. 2010
    ..It is likely that a combination of therapeutic modalities will be required to improve survival and cure rates...
  77. ncbi request reprint Measuring circulating neuroblastoma cells by quantitative reverse transcriptase-polymerase chain reaction analysis
    Irene Y Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York
    Cancer 101:2303-8. 2004
    ..Circulating tumor cells in peripheral blood (PB) derive from depots other than BM, and its measurement may provide additional information in the management of patients with NB...
  78. doi request reprint Reducing epitope spread during affinity maturation of an anti-ganglioside GD2 antibody
    Jian Hu
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Immunol 183:5748-55. 2009
    ..We conclude that epitope spread during affinity maturation can be reduced by negative selection. Furthermore, efficiency of the negative selector depends on its cross-reactive affinity with the matured scFv...
  79. ncbi request reprint High-dose carboplatin-irinotecan-temozolomide: Treatment option for neuroblastoma resistant to topotecan
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York
    Pediatr Blood Cancer 56:403-8. 2011
    ..We report a retrospective study of a novel regimen for neuroblastoma (NB) resistant to standard induction or salvage chemotherapy which now routinely includes topotecan...
  80. pmc Exploiting gene expression profiling to identify novel minimal residual disease markers of neuroblastoma
    Irene Y Cheung
    Department of Pediatrics and Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 14:7020-7. 2008
    ..Because of tumor heterogeneity, no single marker will likely be adequate. Genome-wide expression profiling can uncover potential MRD markers differentially expressed in tumors over normal marrow/blood...
  81. pmc Methionine depletion with recombinant methioninase: in vitro and in vivo efficacy against neuroblastoma and its synergism with chemotherapeutic drugs
    Jian Hu
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, NY 10065, USA
    Int J Cancer 124:1700-6. 2009
    ..rMETase synergized with microtubule depolymerization agents. Moreover, synergism between rMETase and DNA damaging agents was dependent on whether cell lines were established at diagnosis or at relapse...
  82. ncbi request reprint Radically different treatment recommendations for newly diagnosed neuroblastoma: pitfalls in assessment of risk
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Pediatr Hematol Oncol 26:35-9. 2004
    ..Some patients classified as having high-risk neuroblastoma might actually do well with no cytotoxic therapy...
  83. ncbi request reprint Treatment reduction for neuroblastoma
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
    Pediatr Blood Cancer 43:619-21. 2004
  84. ncbi request reprint Exploiting the MIBG-avidity of neuroblastoma for staging and treatment
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Pediatr Blood Cancer 47:863-4. 2006
  85. ncbi request reprint Disialoganglioside GD2 and a novel tumor antigen: potential targets for immunotherapy of desmoplastic small round cell tumor
    Shakeel Modak
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Med Pediatr Oncol 39:547-51. 2002
    ..We examined DSRCT samples for the expression of two tumor antigens that could serve as possible targets for antibody-based immunotherapeutic approaches...
  86. ncbi request reprint Induction for high-risk neuroblastoma
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
    Pediatr Blood Cancer 49:221-3. 2007
  87. doi request reprint A pharmacokinetic model for radioimmunotherapy delivered through cerebrospinal fluid for the treatment of leptomeningeal metastases
    Yonggang Lv
    Department of Biomedical Engineering, The City College of New York, New York, New York 10031, USA
    J Nucl Med 50:1324-31. 2009
    ....
  88. pmc MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors
    Hong Xu
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer Res 69:6275-81. 2009
    ..Differential modulation of this key immunoinhibitory molecule in tumor versus normal tissues may advance both cell-mediated immunotherapy and antibody-based targeted strategies using the B7-H3-specific mAb 8H9...
  89. doi request reprint Intraparenchymal and intratumoral interstitial infusion of anti-glioma monoclonal antibody 8H9
    Neal Luther
    Department of Neurological Surgery, Weill Cornell Medical College, New York, New York 10021, USA
    Neurosurgery 63:1166-74; discussion 1174. 2008
    ..Interstitial delivery of murine immunoglobulin G1 monoclonal antibody (MAb) 8H9 was investigated in a rodent model for the potential treatment of infiltrative gliomas...
  90. ncbi request reprint Monoclonal antibody therapies for solid tumors
    Dimiter V Tassev
    1Gerstner Sloan Kettering Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Expert Opin Biol Ther 9:341-53. 2009
    ..Currently, there are four monoclonal antibodies that have been approved by the FDA for the treatment of solid tumor malignancies. Over 100 other antibodies are in early- and late-phase clinical testing...
  91. ncbi request reprint Neuroblastoma--from genetic profiles to clinical challenge
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, USA
    N Engl J Med 353:2215-7. 2005
  92. ncbi request reprint Novel regions of allelic imbalance identified by genome-wide analysis of neuroblastoma
    Jaume Mora
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Res 62:1761-7. 2002
    ..Spontaneously remitting or quiescent tumors were intact at all of the regions described above...
  93. ncbi request reprint Mechanism by which orally administered beta-1,3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models
    Feng Hong
    Tumor Immunobiology Program of the James Graham Brown Cancer Center, Department of Microbiology and Immunology, University of Louisville School of Medicine, Louisville, KY 40202, USA
    J Immunol 173:797-806. 2004
    ..These granulocytes with CR3-bound beta-1,3-glucan-fluorescein were shown to kill iC3b-opsonized tumor cells following their recruitment to a site of complement activation resembling a tumor coated with mAb...
  94. ncbi request reprint Complement-mediated mechanisms in anti-GD2 monoclonal antibody therapy of murine metastatic cancer
    Masaki Imai
    Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, South Carolina 29424, USA
    Cancer Res 65:10562-8. 2005
    ..The effects of complement can be supplemental to other antibody-mediated mechanisms and likely have increased significance at limiting antibody concentration or low antigen density...
  95. pmc Prospective tracing of MLL-FRYL clone with low MEIS1 expression from emergence during neuroblastoma treatment to diagnosis of myelodysplastic syndrome
    Blaine W Robinson
    Division of Oncology, The Children s Hospital of Philadelphia, University of Pennsylvania School of Medicine 19104 4318, USA
    Blood 111:3802-12. 2008
    ..MLL-FRYL did not increase MEIS1 expression, conferred a proliferative advantage without altering differentiation, and had protracted latency to disease...
  96. ncbi request reprint Evolving significance of prognostic markers associated with new treatment strategies in neuroblastoma
    Jaume Mora
    Department of Oncology, Hospital Sant Joan de Deu de Barcelona, Passeig de Sant Joan de Deu num 2, Barcelona 08950, Spain
    Cancer Lett 197:119-24. 2003
    ..Distinct gene expression patterns between metastatic and non-metastatic NB tumors have been identified. Validation of these results and further mechanistic studies may shed new light on the biology of metastasis in human NB...
  97. ncbi request reprint Clustering of gene hypermethylation associated with clinical risk groups in neuroblastoma
    Miguel Alaminos
    Cancer Epigenetics Laboratory, Spanish National Cancer Centre CNIO, Melchor Fernandez Almagro 3, 28029 Madrid, Spain
    J Natl Cancer Inst 96:1208-19. 2004
    ..Transcriptional silencing of tumor suppressor genes mediated by hypermethylation of promoter CpG islands is a hallmark of human tumors. We addressed the clinical relevance of promoter hypermethylation in neuroblastoma...
  98. pmc Characteristics of stem cells from human neuroblastoma cell lines and in tumors
    Jeanette D Walton
    Laboratory of Neurobiology, Department of Biological Sciences, Fordham University, Bronx, NY 10458, USA
    Neoplasia 6:838-45. 2004
    ..Thus, I-type stem cells may be instrumental in the genesis and growth of tumors in the patient. Their unique biology deserves attention and further investigation...
  99. ncbi request reprint EMP3, a myelin-related gene located in the critical 19q13.3 region, is epigenetically silenced and exhibits features of a candidate tumor suppressor in glioma and neuroblastoma
    Miguel Alaminos
    Cancer Epigenetics Laboratory, Molecular Pathology Programme, Spanish National Cancer Centre, Madrid, Spain
    Cancer Res 65:2565-71. 2005
    ..03) and death of disease (Kendall tau, P = 0.03; r = 0.19). Thus, EMP3 is a good candidate for being the long-sought tumor suppressor gene located at 19q13 in gliomas and neuroblastomas...
  100. ncbi request reprint In vitro and in vivo cytotoxic activities of recombinant immunotoxin 8H9(Fv)-PE38 against breast cancer, osteosarcoma, and neuroblastoma
    Masanori Onda
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute NIH, 37 Convent Drive, Bethesda, MD 20892 4264, USA
    Cancer Res 64:1419-24. 2004
    ..These results make 8H9(dsFv)-PE38 a candidate for further development as a therapeutic agent for breast cancers, osteosarcomas, and neuroblastomas...
  101. pmc Panhandle and reverse-panhandle PCR enable cloning of der(11) and der(other) genomic breakpoint junctions of MLL translocations and identify complex translocation of MLL, AF-4, and CDK6
    Leslie J Raffini
    Division of Oncology, Joseph Stokes, Jr Research Institute, Children s Hospital of Philadelphia, Philadelphia, PA 19104, USA
    Proc Natl Acad Sci U S A 99:4568-73. 2002
    ..The sequences in these three cases show additional MLL genomic breakpoint heterogeneity. Each breakpoint junction suggests nonhomologous end joining and is consistent with DNA damage and repair. CDK6-MLL is a new fusion of both genes...

Research Grants2

  1. Beta glucan enhances antibody therapy for neuroblastoma
    Nai Kong Cheung; Fiscal Year: 2003
    ..These findings will have general implications for antibody and vaccine strategies in human cancer models, and the role of polysaccharides as complementary/herbal medicine in immune-based therapies. ..
  2. A novel set of molecular markers to measure metastatic neuroblastoma
    Nai Kong Cheung; Fiscal Year: 2007
    ..Armed with the tools to collect samples expeditiously and to measure MRD accurately, the paradigm of treating subclinical NB can then be tested in multicenter randomized studies. ..